Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Groh

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2017
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled TrialXavier Puéchal, Christian Pagnoux, Gabriel Baron, et al.
Plos One|September 16, 2017
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patientsMikael Ebbo, Aurélie Grados, Maxime Samson, et al.
Scientific Reports|March 19, 2021
Venous thrombosis and predictors of relapse in eosinophil-related diseasesValériane Réau, Alexandre Vallée, Benjamin Terrier, et al.
Iscience|February 13, 2023
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variantsCamille Chauvin, Laurine Levillayer, Mathilde Roumier, et al.
Autoimmunity Reviews|July 8, 2021
IgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypesAurore Moussiegt, Romain Müller, Mikaël Ebbo, et al.
Rheumatology (Oxford, England)|December 21, 2020
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Matthias Papo, Renato A Sinico, Vítor Teixeira, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European CohortMatthias Papo, Pauline Martinot, Renato A Sinico, et al.
Orphanet Journal of Rare Diseases|April 30, 2023
French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromesMatthieu Groh, Julien Rohmer, Nicolas Etienne, et al.
Annals of the Rheumatic Diseases|September 21, 2023
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective studyBerengere Molina, Roberto Padoan, Maria Letizia Urban, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2017
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled TrialXavier Puéchal, Christian Pagnoux, Gabriel Baron, et al.
Plos One|September 16, 2017
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patientsMikael Ebbo, Aurélie Grados, Maxime Samson, et al.
Scientific Reports|March 19, 2021
Venous thrombosis and predictors of relapse in eosinophil-related diseasesValériane Réau, Alexandre Vallée, Benjamin Terrier, et al.
Iscience|February 13, 2023
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variantsCamille Chauvin, Laurine Levillayer, Mathilde Roumier, et al.
Autoimmunity Reviews|July 8, 2021
IgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypesAurore Moussiegt, Romain Müller, Mikaël Ebbo, et al.
Rheumatology (Oxford, England)|December 21, 2020
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Matthias Papo, Renato A Sinico, Vítor Teixeira, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European CohortMatthias Papo, Pauline Martinot, Renato A Sinico, et al.
Orphanet Journal of Rare Diseases|April 30, 2023
French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromesMatthieu Groh, Julien Rohmer, Nicolas Etienne, et al.
Annals of the Rheumatic Diseases|September 21, 2023
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective studyBerengere Molina, Roberto Padoan, Maria Letizia Urban, et al.
Pageof 12